experiments that the incretin effect, i.e., the augmented insulin secretion seen after oral vs i.v. glucose, is increased in insulin-resistant mice (3) and that the β-cell responsiveness to intravenous glucagon-like peptide-1 (GLP1) is augmented (3, 4
Search Results
Justyna Modrzynska, Christine F Klein, Kasper Iversen, Henning Bundgaard, Bolette Hartmann, Maike Mose, Nikolaj Rittig, Niels Møller, Jens J Holst, and Nicolai J Wewer Albrechtsen
Introduction Glucagon and glucagon-like peptide-1 (GLP-1) are processed from the same precursor, proglucagon ( Fig. 1 ), and have opposite effects on glucose homeostasis ( 1 , 2 , 3 ). In the intestine, proglucagon is cleaved by prohormone
Charlotte Janus, Dorte Vistisen, Hanan Amadid, Daniel R Witte, Torsten Lauritzen, Søren Brage, Anne-Louise Bjerregaard, Torben Hansen, Jens J Holst, Marit E Jørgensen, Oluf Pedersen, Kristine Færch, and Signe S Torekov
for premature mortality ( 4 ). Glucagon-like peptide-1 (GLP-1) is a peptide hormone secreted from intestinal L-cells upon meal intake ( 5 ). GLP-1 stimulates insulin secretion in a glucose-dependent manner – as part of ‘the incretin effect’ – being
Dorte Glintborg, Hanne Mumm, Jens Juul Holst, and Marianne Andersen
). Incretin hormones are released after meal ingestion and account for up to 70% of postprandial insulin secretion ( 3 ). Glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide are the most important incretin hormones. GLP-1 secretion is impaired
C L Bodinham, L Smith, E L Thomas, J D Bell, J R Swann, A Costabile, D Russell-Jones, A M Umpleby, and M D Robertson
investigated. Animal studies have consistently shown that RS improves glucose and insulin metabolism through increased postprandial GLP1 secretion due to stimulation of the colonic enteroendocrine cells (8, 9) . This can result in improved insulin secretion
David P Sonne, Asger Lund, Jens Faber, Jens J Holst, Tina Vilsbøll, and Filip K Knop
i) whether i.v. glucose per se could affect thyroid function parameters and ii) whether any changes could be elicited by infusion of the gastrointestinal hormones glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP1
Jeppe Skov, Jens Juul Holst, Jens Peter Gøtze, Jørgen Frøkiær, and Jens Sandahl Christiansen
Introduction Glucagon-like peptide-1 (GLP1) is a gut-derived incretin hormone with multiple actions in addition to control of glucose homeostasis (1) . Synthetic GLP1 receptor (GLP1R) agonists lower blood pressure in patients with type 2 diabetes
Christine Rode Andreasen, Andreas Andersen, Filip Krag Knop, and Tina Vilsbøll
Introduction Glucagon-like peptide 1 (GLP-1) is a gut-derived glucoregulatory hormone secreted in response to food consumption. Human GLP-1 is synthesised from the proglucagon gene and is secreted from the enteroendocrine L cells ( 1 ). Some
Nicolai J Wewer Albrechtsen, Monika J Bak, Bolette Hartmann, Louise Wulff Christensen, Rune E Kuhre, Carolyn F Deacon, and Jens J Holst
Introduction Glucagon-like peptide 1 (GLP-1) and glucagon arise from differential processing of the glucagon precursor, proglucagon (PG) (1) . Both peptides are important for normal glucose homeostasis, which focused interest on their potential
Jukka Koffert, Henri Honka, Jarmo Teuho, Saila Kauhanen, Saija Hurme, Riitta Parkkola, Vesa Oikonen, Andrea Mari, Andreas Lindqvist, Nils Wierup, Leif Groop, and Pirjo Nuutila
circulation. When Kogire and co-workers ( 10 ) injected GIP to healthy dogs, they observed increased BF in SMA but not in CA, suggesting that GIP contributes to the redistribution of BF after a meal. Similar results have been reported for GLP-1 ( 11 ). However
